Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

nding the current product label into adult AML. Preliminary data has been accepted for presentation at ASCO this spring and a supplemental new drug application (sNDA) for clofarabine is expected to be filed in the second half of this year. It is possible that data from this study also could be considered for part of a new filing with EMEA.

Evoltra is currently indicated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens. The withdrawal of the European application of Evoltra in adult AML has no consequences for patients enrolled in current clinical trials or compassionate use programs.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including the expected results of the data generated from clofarabine clinical trials, the presentation and use of this data to support regulatory filings, and t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Rancho BioSciences , the scientific ... Array Suite with tranSMART . Scientists that ... send data in tranSMART to Array Suite for further ... tranSMART including the new 1.2 release. Array Suite ... for the analysis of high dimensional quantification data, including ...
(Date:7/31/2014)... “Rapid technological advances will spread ... increasing unemployment, depressing American consumer spending and further ... Catch 22—we need automated manufacturing if we are ... says economist and corporate relocation expert Dr. Ron ... Pro-Business States for 2014, co-published with the American ...
(Date:7/31/2014)... The Kidney Cancer Association (KCA) has established a CNN iReport ... News. , Bill Bro, KCA CEO, says, “We’re pleased ... international news organization. When we began using iReport last month, ... program highlights news of an enzyme that is lost in ... Kidney Cancer News also presents a report on outcomes from ...
(Date:7/30/2014)... Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended June 30, 2014 on Wednesday, August ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its second quarter 2014 ...
Breaking Biology Technology:Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... PLYMOUTH MEETING, Pa., March 17 /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... for the fourth quarter and fiscal year ended,December 31, 2008. , ... -- Fourth quarter revenues increased to $36.6 million, ... fourth quarter of 2007., -- Non-GAAP operating income, ...
... Biotek, an innovative Canadian biotechnology company focusing primarily ... protein purification, today announced the signing of an ... "EXQ") to supply RNA purification kits based on ... Denmark-based company active in the life sciences, diagnostics ...
... of 25 February 2009, Arpida communicated that the Board of ... the company,s future. , In preparation ... to update shareholders as follows: At the shareholders, meeting, the,Board ... following options or a combination thereof: , , ...
Cached Biology Technology:BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 2BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 3BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 4BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 5BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 6BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 7BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 8BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 9BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 10BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 11BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results 12Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 2Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 3Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S 4Board Reviews Strategic Options to Present to Shareholders at Shareholders' Meeting 2
(Date:7/31/2014)... University researchers have completed a 20-year study that ... prairie at different times of the year. It ... spring time frame has no measurable negative consequences ... multiple benefits. , The study was conducted by ... Biological Station fire chief, and Joseph Craine, research ...
(Date:7/31/2014)... percent of animal models against the highly infectious and ... intestinal disease that kills approximately 30,000 Americans annually. The ... and Immunity . , In the study, the ... purified toxins produced by C. difficile , as ... model that mimics the human disease, after only two ...
(Date:7/31/2014)... Alexandre Edmond Becquerel first discovered the photovoltaic effect in ... the power of sunlight for its own purposes. In ... issue of the FASEB Journal , ... the power of sunlight by focusing on a naturally ... throughout evolution. This conservationor persistence over time and across ...
Breaking Biology News(10 mins):Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists shine bright new light on how living things capture energy from the sun 2
... mice of immune cells that promote the formation of new ... painful condition associated with infertility that affects up to 15 ... of new blood vessels, or angiogenesis, is known to encourage ... led by Ofer Fainaru, MD, PhD, a research associate in ...
... Resilience and Adaptation Program at the University of ... from the National Science Foundation to address questions ... RAP focuses on answering questions of how global ... as indigenous subsistence hunting. Economic, cultural and ecological ...
... Fla. Shiny amber jewelry and a mucky Florida ... ecosystem that could be anywhere from 15 million to ... of Florida and the Museum of Natural History in ... such as beetles and small crustaceans unwittingly swim into ...
Cached Biology News:Immune cells promote blood vessel formation in mouse endometriosis 2Alaska graduate program in sustainability receives $3.2 million award 2Scientists find how amber becomes death trap for watery creatures 2Scientists find how amber becomes death trap for watery creatures 3
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... Complete kit for all types of yeast ... Choice of two ... self-activating baits , ... , Complete set ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: